COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Scarfò, Lydia; Chatzikonstantinou, Thomas; Rigolin, Gian Matteo; Quaresmini, Giulia; Motta, Marina; Vitale, Candida; Garcia-Marco, Jose Antonio; Hernández-Rivas, José Ángel; Mirás, Fatima; Baile, Mónica; Marquet, Juan; Niemann, Carsten U; Reda, Gianluigi; Munir, Talha; Gimeno, Eva; Marchetti, Monia; Quaglia, Francesca Maria; Varettoni, Marzia; Delgado, Julio; Iyengar, Sunil; ... (2020). COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia, 34(9), pp. 2354-2363. Nature Publishing Group 10.1038/s41375-020-0959-x

[img] Text
COVID-19_severity_and_mortality_in_patients_.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Haematology and Central Haematological Laboratory

UniBE Contributor:

Andres, Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0887-6924

Publisher:

Nature Publishing Group

Language:

English

Submitter:

Pierrette Durand Lüthi

Date Deposited:

15 Dec 2020 17:55

Last Modified:

15 Dec 2020 17:55

Publisher DOI:

10.1038/s41375-020-0959-x

PubMed ID:

32647324

BORIS DOI:

10.7892/boris.149539

URI:

https://boris.unibe.ch/id/eprint/149539

Actions (login required)

Edit item Edit item
Provide Feedback